Zhitong Finance App News, Shisi Pharmaceutical Group (02005.HK) announced that the Group's mabalosavir has been approved by the China National Drug Administration to register as an active ingredient for use in marketed formulations, and is the third domestic company to be approved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.